Department of Neurology, Medical University of Innsbruck, Christoph-Probst-Platz 1, 6020, Innsbruck, Austria.
Department of Neurology, Medical University of Innsbruck, Christoph-Probst-Platz 1, 6020, Innsbruck, Austria.
Sleep Med. 2020 Nov;75:456-458. doi: 10.1016/j.sleep.2020.09.010. Epub 2020 Sep 10.
We assessed frontal executive functions in patients with RLS/WED with and without augmentation and compared the results to healthy controls.
We recruited 38 patients with RLS/WED. A total of 23 patients were treated with dopaminergic therapy and showed no signs of augmentation and 15 patients had a history of augmentation (AUG). Results were compared to 21 healthy controls. All individuals were assessed by the Frontal Assessment Battery (FAB) and the MMSE. Furthermore, impulsivity was assessed during a semi-structured interview.
Patients with AUG performed worse in the FAB than healthy controls and RLS/WED patients without AUG (p = 0.001, η = 0.201). When we assessed the subtests of the FAB separately, we found a significant difference in the subtest assessing inhibitory control (p = 0.008, η = 0.138).
Our findings suggest an impaired executive function in RLS/WED patients with augmentation compared to RLS/WED patients without augmentation and healthy controls. Long term neuroplastic changes within the prefrontal cortex may be the underlying cause for these results. However, further studies in a larger sample size and with a more extensive neuropsychological test battery are needed to confirm our preliminary results.
我们评估了伴有和不伴有进展的 RLS/WED 患者的额叶执行功能,并将结果与健康对照组进行比较。
我们招募了 38 名 RLS/WED 患者。其中 23 名患者接受了多巴胺能治疗,且没有进展的迹象,15 名患者有进展的病史(AUG)。结果与 21 名健康对照者进行比较。所有个体均通过额叶评估量表(FAB)和简易精神状态检查(MMSE)进行评估。此外,在半结构化访谈中评估了冲动性。
与健康对照组和无进展的 RLS/WED 患者相比,有进展的患者在 FAB 中的表现更差(p=0.001,η=0.201)。当我们分别评估 FAB 的子测试时,我们发现抑制控制子测试存在显著差异(p=0.008,η=0.138)。
与无进展的 RLS/WED 患者和健康对照组相比,有进展的 RLS/WED 患者的执行功能受损。前额叶皮层内的长期神经可塑性变化可能是导致这些结果的原因。然而,需要更大样本量和更广泛的神经心理学测试组合的进一步研究来证实我们的初步结果。